G
Giraffe Bio
Biochemical flotation reagents that improve copper recovery and selectivity for mining operators
About Giraffe Bio
Giraffe Bio is at the forefront of revolutionizing the mining industry with its proprietary hardware and cell-free systems for protein synthesis and expression. The company leverages advanced technologies such as lithography and microfluidics to create biochips that are densely packed with biomolecules, enabling high throughput testing. This precision technology allows for the rapid identification of optimal candidates for metal extraction, particularly focusing on critical minerals like copper and lithium. By synthesizing proteins directly on biochips, Giraffe Bio efficiently tests their interactions with mining samples, building a comprehensive data library for further optimization. The company's approach addresses the economic inefficiencies and environmental challenges associated with traditional metal extraction methods, aiming to improve efficiency, reduce processing times, and minimize water usage. Operating in the mining sector, Giraffe Bio serves clients seeking sustainable and efficient solutions for mineral extraction. The business model is centered around providing cutting-edge biochip technology and data-driven insights to enhance the extraction processes of its clients, thereby generating revenue through the sale and licensing of its proprietary systems.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2024
- Headquarters
- Argentina
- Employees
- 13
- Open positions
- 1
- Dealroom signal
- 76.7/100
- Sector
- Energy, Mining Technologies, Biotechnology, Sustainable Development Goals, Climate Tech, Lithium Mining, Metal
- Technology
- Artificial Intelligence, Hardware, Big Data, Deep Tech, Machine Learning, Deep Learning
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SUPPORT PROGRAM✓Other financing | May 2026 | $0 | — | Third Derivative | ↗ |
| SEED✓Equity / VC | Dec 2024 | $0 | — | Indie Bio · SOSV | ↗ |
Growth signals
Latest recorded traffic for Giraffe Bio is 2.8K monthly website visits, up 1066.7% over the last three months. Giraffe Bio's team grew 85.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Indie Bio
SOSV
Other known investors1 additional known investor
Third Derivative
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Giraffe Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Giraffe Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







